Baumgarten C R, O'Connor A, Dokic D, Schultz K D, Kunkel G
Universitätsklinikum Rudolf Virchow, Clinical Immunology and Asthma OPD, Freie Universität Berlin, Germany.
Clin Exp Allergy. 1997 Nov;27(11):1322-7.
Bradykinin, a potent inflammatory mediator, is released during allergic and non-allergic rhinitis and asthma in man. Nasal bradykinin challenge induces a dose-dependent plasma leakage into the nasal cavity and relevant symptoms of rhinitis.
We now report on substance P generation during nasal bradykinin challenge in vivo.
The effect of locally applied bradykinin on substance P generation was studied in nine individuals, allergic to grass pollen and six non-allergic controls. In the allergics TAME-esterase activity, histamine and substance P concentrations were measured in nasal lavages and correlated to the clinical symptoms.
Substance P concentrations in nasal lavages increased in a dose-dependent fashion during nasal bradykinin challenge in both groups. In the allergic group Substance P-increases correlated with the production of TAME-esterase activity (r = 0.9, P < 0.05) whereas these allergic individuals did not produce any histamine increases. The generation of substance P and the increase of TAME-esterase activity was associated with the onset of clinical symptoms. Correlation of oedema and hypersecretion to substance P were significant by linear regression analysis (r = 0.88, P < 0.005 and r = 0.89, P < 0.02, respectively). Bradykinin induced irritations like burning and itching were short-term and rare. Serial dilutions of nasal washes produced Substance P-RIA displacement curves that paralleled the standard curve and recovery of standard substance P that was added to nasal washes was 76 +/- 4% (mean +/- SEM), n = 8.
Bradykinin induces in vivo a dose-dependent plasma leakage into the nasal cavity without affecting mast cells, but stimulates nerve endings resulting in the release of the neuropeptide substance P.
缓激肽是一种强效炎症介质,在人类过敏性和非过敏性鼻炎及哮喘发作时释放。鼻腔缓激肽激发试验可诱导剂量依赖性血浆渗漏至鼻腔并引发相关鼻炎症状。
我们现在报告体内鼻腔缓激肽激发试验期间P物质的产生情况。
在9名对草花粉过敏的个体和6名非过敏对照者中,研究局部应用缓激肽对P物质产生的影响。在过敏者中,测量鼻腔灌洗液中的TAME酯酶活性、组胺和P物质浓度,并将其与临床症状相关联。
两组在鼻腔缓激肽激发试验期间,鼻腔灌洗液中的P物质浓度均呈剂量依赖性增加。在过敏组中,P物质增加与TAME酯酶活性产生相关(r = 0.9,P < 0.05),而这些过敏个体的组胺未产生任何增加。P物质的产生和TAME酯酶活性的增加与临床症状的发作相关。通过线性回归分析,水肿和分泌亢进与P物质的相关性显著(分别为r = 0.88,P < 0.005和r = 0.89,P < 0.02)。缓激肽引起的烧灼感和瘙痒等刺激是短期且少见的。鼻腔冲洗液的系列稀释产生的P物质放射免疫分析位移曲线与标准曲线平行,添加到鼻腔冲洗液中的标准P物质回收率为76 +/- 4%(平均值 +/- 标准误),n = 8。
缓激肽在体内诱导剂量依赖性血浆渗漏至鼻腔,不影响肥大细胞,但刺激神经末梢导致神经肽P物质释放。